Related Experiment Video
Updated: Jan 20, 2026

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
Published on: February 27, 2019
Rapid tumor regression from PD-1 inhibition after anti-CD19 chimeric antigen receptor T-cell therapy in refractory
Brian T Hill1, Zachary J Roberts2, Allen Xue2
1Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, USA. HillB2@ccf.org.
No abstract available in PubMed .
Related Concept Videos
08:04In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
10:29Generation of Human Chimeric Antigen Receptor Regulatory T Cells
04:42An Ex Vivo Technique to Generate Tumor-Specific Chimeric Antigen Receptor T Cells
02:42An In Vitro Assay to Evaluate the Anti-Tumor Activity of Tumor-Specific CAR T Cells
04:38An Ex Vivo Technique to Manufacture Chimeric Antigen Receptor T Cells
10:52Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

